Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
This randomized phase II trial studies how well lenalidomide improves immune response to
 pneumococcal 13-valent conjugate vaccine in patients with chronic lymphocytic leukemia, small
 lymphocytic lymphoma, or monoclonal B cell lymphocytosis. Biological therapies, such as
 lenalidomide, use substances made from living organisms that may stimulate or suppress the
 immune system in different ways and stop cancer cells from growing. Lenalidomide may also
 improve the effectiveness of pneumococcal 13-valent conjugate vaccine that is used to prevent
 infection.
PRIMARY OBJECTIVES:

 I. To assess the ability of a 6 week course of low dose lenalidomide to improve the
 proportion of patients with monoclonal B cell lymphocytosis (MBL) and chronic lymphocytic
 leukemia (CLL) who develop an immune response to pneumococcal vaccination as measured by the
 proportion of patients with >= 4-fold rise from pre-vaccine (day 15) for >= 2 of the 3
 serotypes measured at 28 days post-vaccination by opsonophagocytic activity (OPA) of
 antibodies from sera.

 SECONDARY OBJECTIVES:

 I. Evaluate disease status by physical exam and complete blood counts in patients
 participating in each arm of the study at the time of the 6 week assessment of immune
 response.

 II. Evaluate time to treatment for progressive CLL for patients on each study arm.

 III. Evaluate the adverse events profile in each study arm.

 TERTIARY OBJECTIVES:

 I. To assess the immune response to pneumococcal vaccination as measured by fold-change from
 pre-vaccine (day 15) to 28 days post-vaccination in OPA geometric mean titers (GMT) of
 antibodies from sera.

 II. To assess the immune response to pneumococcal vaccination as measured by fold-change from
 pre-vaccine (day 15) to 28 days post-vaccination in quantitative Streptococcus pneumoniae
 immunoglobulin G (IgG) GMT of antibodies from sera.

 III. Evaluate the effect of 6 weeks of low dose lenalidomide on global immune function
 including T-cell repertoire, T-cell immune synapse, serum immunoglobulin levels, and absolute
 numbers of T-cell and natural killer (NK) cells.

 OUTLINE: Patients are randomized 1 of 2 treatment arms.

 ARM I: Patients receive lenalidomide orally (PO) once daily (QD) on days 1-42 and
 pneumococcal 13-valent conjugate vaccine intramuscularly (IM) on day 15.

 ARM II: Patients receive pneumococcal 13-valent conjugate vaccine IM on day 15.

 After completion of study treatment, patients are followed up at day 28, and then every 6
 months for up to 2 years.
Inclusion Criteria:

 -  Diagnosis of:

 1. CLL according to the National Cancer Institute (NCI) criteria

 2. Small lymphocytic lymphoma (SLL) according to the World Health Organization (WHO)
 criteria

 3. MBL according to the consensus criteria

 -  This includes previous documentation of:

 -  Biopsy-proven small lymphocytic lymphoma or

 -  Diagnosis of CLL or MBL as evidenced by all of the following:

 -  Clonal B-cell population in the peripheral blood with
 immunophenotyping consistent with CLL defined as:

 -  The population of lymphocytes share both B-cell antigens
 (cluster of differentiation [CD]19, CD20 [typically dim
 expression], or CD23) as well as CD5 in the absence of other
 pan-T-cell markers (CD3, CD2, etc)

 -  Clonality as evidenced by k (kappa) or lambda light chain
 expression (typically dim immunoglobulin expression) or other
 genetic method (e.g. immunoglobulin heavy chain variable
 [IGHV] analysis) NOTE: splenomegaly, hepatomegaly, or
 lymphadenopathy are not required for the diagnosis of CLL

 -  Patients with a peripheral blood B-cell lymphocyte count of < 5 x
 10^9/L and no evidence of lymphadenopathy or organomegaly will be
 classified as MBL; patients with a peripheral blood B-cell
 lymphocyte count of < 5 x 10^9/L who have evidence of
 lymphadenopathy will be classified as SLL; patients with a
 peripheral blood B-cell lymphocyte count >= 5 x 10^9/L will be
 considered to have CLL

 -  Before diagnosing MBL, CLL or SLL, mantle cell lymphoma must be
 excluded by demonstrating a negative fluorescence in situ
 hybridization (FISH) analysis for t(11;14)(IgH/cyclin D 1 [CCND1])
 on peripheral blood or tissue biopsy or negative
 immunohistochemical stains for cyclin D1 on involved tissue biopsy

 -  CLL or SLL patients only (does not apply to MBL patients): Rai stage 0-1 (both CLL and
 SLL patients can be staged using the Rai system)

 -  Patients must not previously have received the Prevnar 13 pneumococcal vaccination;
 NOTE: previous vaccination with Pneumovax (PCV23) is permitted but must have been at
 least 365 days prior to registration

 -  Patients must be previously untreated and must NOT have any of the following
 indications for chemotherapy:

 -  Evidence of progressive marrow failure as manifested by the development of or
 worsening anemia (=< 11 g/dL) and/or thrombocytopenia (=< 100 x 10^9/L) not due
 to autoimmune disease

 -  Symptomatic or progressive lymphadenopathy, splenomegaly or hepatomegaly

 -  One or more of the following disease-related symptoms:

 -  Weight loss >= 10% within the previous 6 months

 -  Extreme fatigue attributed to CLL

 -  Fevers > 100.4 degree Fahrenheit (o^F) for 2 weeks without evidence of
 infection

 -  Drenching night sweats without evidence of infection Note: 1) Prior
 chemotherapy or monoclonal antibody based therapy for treatment of CLL or
 SLL will be considered prior therapy; nutraceutical treatments with no
 established benefit in CLL (such as epigallocatechin gallate or EGCG, found
 in green tea or other herbal treatments) will not be considered "prior
 treatment" 2) Prior corticosteroid therapy for an indication other than
 CLL/SLL will not be considered "prior treatment"; previous use of
 corticosteroids for treatment of autoimmune complications of CLL/SLL does
 not constitute prior therapy for CLL/SLL

 -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

 -  Absolute neutrophil count (ANC) >= 1000/mm^3

 -  Platelet count >= 100,000/mm^3

 -  Hemoglobin >= 11.0 g/dL

 -  Total bilirubin =< 1.5 x upper limit of normal (ULN) unless due to Gilbert's disease;
 if total bilirubin is > 1.5 x ULN, a direct bilirubin should be performed and must be
 < 1.5 mg/dL for Gilbert's to be diagnosed

 -  Aspartate transaminase (AST) =< 3 x ULN

 -  Calculated creatinine clearance must be >= 50 ml/min using the Cockcroft-Gault formula

 -  Provide informed written consent

 -  Willing to return to enrolling institution for follow-up (during the active monitoring
 phase of the study)

 -  All study participants must be willing to be registered into the mandatory Revlimid
 Risk Evaluation and Mitigation Strategy (REMS)® program, and be willing and able to
 comply with the requirements of the REMS® program; NOTE: Actual registration in the
 Revlimid REMS® program may occur after the patient is randomized since this
 requirement only applies to patients randomized to Arm A

 -  Females of reproductive potential must be willing to adhere to the scheduled pregnancy
 testing as required in the Revlimid REMS® program; NOTE: This requirement only applies
 to patients randomized to Arm A

 -  Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients
 intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight
 heparin)

 -  Willing to provide blood samples for correlative research purposes

 Exclusion Criteria:

 -  Palpable lymph nodes > 3 cm in maximal dimension

 -  Any of the following:

 -  Pregnant women

 -  Nursing women

 -  Men or women of childbearing potential who are unwilling to employ adequate
 contraception

 -  Any of the following comorbid conditions:

 -  New York Heart Association classification III or IV cardiovascular disease

 -  Recent myocardial infarction (=< 30 days)

 -  Uncontrolled infection

 -  Immunocompromised patients and patients known to be human immunodeficiency virus (HIV)
 positive and currently receiving antiretroviral therapy; NOTE: patients known to be
 HIV positive, but without clinical evidence of an immunocompromised state, are
 eligible for this trial

 -  Other active primary malignancy requiring treatment or limiting survival to =< 2 years
 prior to registration

 -  Any radiation therapy =< 28 days prior to registration

 -  Any major surgery =< 28 days prior to registration

 -  Current use of corticosteroids; EXCEPTION: low doses of steroids (=< 10 mg of
 prednisone or equivalent dose of other steroid) used for treatment of nonhematologic
 medical conditions; NOTE: previous use of corticosteroids is allowed

 -  Active hemolytic anemia requiring immunosuppressive therapy or other pharmacologic
 treatment; NOTE: patients who have a positive Coombs test but no evidence of hemolysis
 are NOT excluded from participation

 -  History of deep venous thromboses or pulmonary embolism =< 365 days prior to
 registration

 -  Co-existent diffuse large B-cell lymphoma (Richter's transformation)